PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor ...

Incyte is gunning for a first-in-class nod for PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA in 2021. The addition of Zynyz to chemotherapy significantly reduced the ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PD-1 blockade conferred benefit to certain women with ...

Vaginal lacerations during laparoscopic hysterectomy for endometrial cancer and local recurrence risk. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

SAN DIEGO -- Injecting the PD-1 inhibitor nivolumab (Opdivo) directly into high-risk oral precancers proved safe and reduced lesion size in the vast majority of patients enrolled in a small phase I ...